Key result
Only 10.6% of stroke patients with non-valvular atrial fibrillation treated with vitamin K antagonists had a therapeutic INR, and only 15.4% of treated patients received NOACs.
Why the study?
Atrial fibrillation is the most frequent cause of cardioembolic stroke, but patterns of real-life anticoagulant treatment among patients admitted for stroke due to non-valvular atrial fibrillation needed evaluation.
What are the real-world patterns of anticoagulant treatment and adherence in patients with non-valvular atrial fibrillation admitted for stroke in Romania?
Observational (n=108)
No
What are the real-world patterns of anticoagulant treatment and adherence in patients with non-valvular atrial fibrillation admitted for stroke in Romania?
In a Romanian real-world setting, a significant proportion of NVAF patients admitted for stroke are either not prescribed anticoagulants, non-adherent, or suboptimally controlled on vitamin K antagonists.
Suboptimal anticoagulation persists among Romanian NVAF stroke patients; leaves open whether targeted education or NOAC access improves adherence and outcomes.
Atrial fibrillation (AF) represents the most frequent cause of cardioembolic stroke. The aim of the study was to evaluate the patterns of anticoagulant treatment in patients admitted for stroke due to non-valvular atrial fibrillation (NVAF). The main inclusion criteria in the study was the diagnosis of cardioembolic stroke in patients admitted to our hospital between November 2016 and February 2017. We evaluated different subtypes of AF related to stroke. A number of 108 patients with NVAF were included. Of the 90 patients known with NVAF, 41 had received recommendation for anticoagulant therapy, but only 27 followed the treatment. An important percentage of patients with stroke, treated with vitamin K antagonists (VKA), were not optimally anticoagulated, being at risk both for thromboembolic risk and haemorrhagic events. An important percentage of patients with stroke, treated with VKA, are not optimally controlled (INR outside the therapeutic range), exposing them at risk for thromboembolic and also haemorrhagic events. In real life settings, in Romania, only a small number of patients with NVAF receive NOAC treatment.
No takes yet. Share an insight, caveat, or question.
M Sabău (2020) conducted an observational in Cardioembolic stroke due to non-valvular atrial fibrillation (n=108). Anticoagulant therapy was evaluated. Only 10.6% of stroke patients with non-valvular atrial fibrillation treated with vitamin K antagonists had a therapeutic INR, and only 15.4% of treated patients received NOACs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: